INTRODUCTION
Accepted: December 27, 1999 During the past two decades, major strides have been improved (1, 2) . However, the price that many young have reported that semen quality is poor in patients possible to use a single motile sperm for fertiliza-
Conclusions:
The two patient groups in this study had poor tion (10,11).
semen quality when compared with healthy donors both
The purpose of our study was to (a) examine semen before and after cryopreservation. Sarcoma establish the value of cryopreservation in these patients before they start therapy.
PATIENTS AND METHODS
consent was obtained from all subjects. Records of 14 Santa Ana, CA). An aliquot of freezing medium equal to 25% of the original specimen volume was added to patients with different types of sarcoma aged 22 to 31 years and 21 patients with different types of carcinoma the specimen and gently mixed for 5 min using an aliquot mixer (Hema-tek; Miles Scientific, Elkhart, referred to the sperm bank at our institution for sperm cryopreservation between 1982, when the sperm bank IN). This procedure was repeated until the volume of cryoprotectant added equaled the volume of the was established, and 1997 were reviewed. The results were compared to those of 50 normal healthy donors ejaculate. Cryovials were frozen at Ϫ20ЊC for 8 min and then in liquid nitrogen vapor at Ϫ100ЊC for 2 h. aged 23 to 35 years. Patients were included in this study only if they banked specimens before starting
The vials were then transferred to liquid nitrogen at Ϫ196ЊC for long-term storage. On the day after the treatment. Patients with sarcoma had the following diagnoses: prostate sarcoma (n ϭ 1), malignant semen was frozen, a vial was removed and thawed by incubation at 37ЊC for 20 min. A 5-l aliquot was schwannoma (n ϭ 1), osteogenic sarcoma (n ϭ 2), neurofibrosarcoma (n ϭ 1), primitive neuroectodermal analyzed as described above. tumor (n ϭ 1), Ewing's sarcoma (n ϭ 5), synovial sarcoma (n ϭ 1), and rhabdomyosarcoma (n ϭ 2).
Statistical Analysis Patients with carcinoma had the following diagnoses: thyroid carcinoma (n ϭ 1), squamous cell carcinoma All statistical analyses were performed with the SAS of the larynx (n ϭ 1), adenocarcinoma of the tongue statistical software package (SAS Institute Inc., Cary, (n ϭ 1), small cell carcinoma of the lung (n ϭ 2), NC). The pairwise Wilcoxon rank-sum test was pergastric adenocarcinoma (n ϭ 1), colon adenocarciformed to compare the prefreeze and postthaw semen noma (n ϭ 2), prostate adenocarcinoma (n ϭ 5), and analysis results of the healthy donors and the patients. undifferentiated carcinoma (n ϭ 8).
In addition, age and ejaculate volumes were compared Patient information (age, type of disease) was using the pairwise Wilcoxon rank-sum test. A P value obtained from medical records and when necessary by of Ͻ.05 was considered significant, and all summary phone calls to the patients or to the referring physician.
statistics are presented as median and interquartile ranges.
Donor Selection
For the donor population, inclusion criteria were RESULTS an ejaculate volume of at least 2 ml and a sperm concentration of at least 20 ϫ 10 6 /ml of which at least 50% were motile and 30% had normal sperm Sperm characteristics before and after cryopreservamorphology according to the World Health Organization in healthy donors, men with sarcoma, and men tion (WHO) classification (12).
with carcinoma are compared in Table I significantly older than patients with sarcoma ysis Corporation, Palo Alto, CA). Manual verification (P ϭ .04). Also, the ejaculate volume of patients with of the semen analyzer results was performed by microsarcoma was significantly higher than that of patients scopic examination. (TMS), percent motility, curvilinwith carcinoma (P ϭ .007). ear velocity (VCL), linearity (LIN), and amplitude of lateral displacement (ALH) were measured.
Semen Quality Before Cryopreservation Semen Cryopreservation
Median TMS, percent motility, and LIN were significantly lower in patients with carcinoma than in Sperm were cryopreserved with a glycerol-based cryoprotectant, TEST-Yolk buffer (Irvine Scientific, healthy donors (Table I) . Median TMS was signifi-HALLAK, MAHRAN, CHAE, AND AGARWAL suggested that the stress of discovering that one has a potentially fatal disease requiring unpleasant treatment might be sufficient to lower semen quality. It also may Semen Quality After Cryopreservation result from nutritional deficiency or from the systemic Median postthaw TMS was significantly lower in consequences of cancer itself (17). patients with carcinoma than in healthy donors (Table  Therapeutic advances have made curing many I). Median VCL and LIN were lower in carcinoma malignant diseases a realistic goal (19) . Unfortunately, patients than in healthy donors. Only ALH was signifitreatment regimens such as chemotherapy, radiothercantly lower in the sarcoma patients than in healthy apy, surgery, or a combination of these treatments fredonors.
quently result in permanent infertility (1) . Gonadal damage induced by chemotherapeutic agents usually occurs within 90 to 120 days of chemotherapy induc-DISCUSSION tion, resulting in various degrees of oligozoospermia, necrozoospermia, or azoospermia (20) . The duration Sarcomas are rare tumors accounting for approxiand severity of spermatogenic suppression are depenmately 8000 cases per year in the United States, dent on the agents involved, the time course of treatwhereas the different types of carcinomas combined ment, and the total dose of agents. Alkylating agents are responsible for more than 500,000 new cases per and procarbazine are the most damaging to spermatoyear (13). Surprisingly, there are few reports on sperm genesis (20, 21) . cryopreservation in patients with any type of carciHowever, surviving malignancy patients, especially noma or sarcoma (13-15).
those of reproductive age, may wish to have children In testicular cancer, the cancer may be directly after an interval free of the disease (22). Therefore, related to poor semen quality (8,16). Also, several sperm banking is considered "fertility insurance" in brain tumors can cause hyperprolactinemia, which in patients with malignancy who require potential spermturn causes gonadal dysfunction, decreased libido, and atotoxic treatment for cure (23), especially with the impotence (17). However, the explanation of the poor recent advances in assisted reproductive techniques. semen quality in many patients with other types of malignant diseases, such as sarcoma and carcinoma, With ICSI, men with even the most severe forms of 
